Asklepios BioPharmaceutical
Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies for genetic disorders and rare diseases. The company leverages its proprietary AAV technology and advanced manufacturing capabilities to support a robust pipeline of clinical programs, which includes treatments for Pompe disease and congestive heart failure, along with a diverse array of preclinical therapeutics targeting neuromuscular and central nervous system conditions. Additionally, Asklepios has out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. Its gene therapy platform features Pro10, a proprietary cell line manufacturing process, and a comprehensive library of AAV capsids and promoters. Founded in 2001 and headquartered in Research Triangle Park, North Carolina, Asklepios BioPharmaceutical is committed to advancing genetic medicine through extensive global research collaborations and innovative delivery methods.
Brainvectis SAS is a French company that develops gene therapy treatments for neurodegenerative diseases, specifically targeting the cholesterol pathway in the brain. Founded in 2015 by Nathalie Cartier Lacave, the company focuses on restoring normal cholesterol metabolism by delivering CYP46A1, a critical enzyme, into patients' brains. This innovative approach aims to address conditions such as Alzheimer's and Huntington's diseases. Headquartered in Fontenay-aux-Roses, France, Brainvectis operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
RoverMed BioSciences specializes in precision targeted drug delivery technology designed to effectively deliver life-saving medications to challenging disease sites within the body. The company has developed a twenty nanometer nanocapsule technology that allows for the intact delivery of therapeutic cargo directly into the nucleus of target cells, irrespective of their location. This innovative approach has been validated through extensive research and development conducted by GeneSegues Therapeutics. Initially focused on solid tumor cancers of the head and neck, prostate, and colon, RoverMed is now expanding its applications in collaboration with larger pharmaceutical partners. By integrating its drug delivery technology with the drugs of its partners, RoverMed aims to enhance therapeutic options for a range of difficult-to-treat diseases, thereby addressing significant unmet medical needs.
Synpromics Ltd. specializes in the development and commercialization of synthetic promoters that regulate gene expression. Founded in 2010 and located in Edinburgh, United Kingdom, the company focuses on enhancing the safety and efficacy of cell and gene therapies through its proprietary genomics and bioinformatics technologies. By utilizing a comprehensive bioinformatics database, Synpromics enables the design and selection of product-specific promoters, which supports biological researchers and developers in creating innovative solutions in the fields of AgBio and bioprocessing. As of 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.